Metabolomics and pharmacokinetics of Corni Fructus in ameliorating myocardial ischemic injury.
10.19540/j.cnki.cjcmm.20241221.201
- Author:
Xiang-Feng LIU
1
;
Yu WU
1
;
Chao-Yan YANG
1
;
Hua-Wei LIAO
1
;
Yan-Fen CHEN
1
;
Xin HE
1
;
Ying-Fang WANG
1
;
Jin-Ru LIANG
1
Author Information
1. School of Traditional Chinese Medicine, Guangdong Pharmaceutical University Guangzhou 510006, China.
- Publication Type:Journal Article
- Keywords:
Corni Fructus;
metabolomics;
myocardial ischemia;
pharmacokinetics
- MeSH:
Animals;
Cornus/chemistry*;
Mice;
Metabolomics;
Drugs, Chinese Herbal/administration & dosage*;
Male;
Myocardial Ischemia/metabolism*;
Humans;
Troponin I/metabolism*;
Myocardium/pathology*;
Disease Models, Animal;
Biomarkers/metabolism*;
Creatine Kinase, MB Form/metabolism*
- From:
China Journal of Chinese Materia Medica
2025;50(5):1363-1376
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to investigate the ameliorating effect of Corni Fructus(CF) on the myocardial ischemic injury and the pharmacokinetic properties of characteristic components of CF. The mouse model of isoproterenol-induced myocardial ischemia was established and administrated with the aqueous extract of CF. The general efficacy of CF in ameliorating the myocardial ischemic injury was evaluated based on the cardiac histopathology and the levels of myocardial injury markers: creatine kinase isoenzyme(CK-MB) and cardiac troponin I(cTn-I). The metabolomics analysis was carried out for the heart and serum samples of mice to screen the biomarkers of CF in ameliorating the myocardial ischemic injury and then the predicted biomarkers were submitted to metabolic pathway enrichment. The pharmacokinetic analysis was performed for morroniside, loganin, and cornuside Ⅰ in mouse heart and serum samples to obtain the pharmacokinetic parameters of these components. The pharmacokinetic parameters were then integrated on the basis of self-defined weighting coefficients to simulate an integrated pharmacokinetic profile of CF iridoid glycosides in the heart and serum of the mouse model of myocardial ischemia. The results indicated that CF reduced the pathological damage to cardiac cells and tissue(hematoxylin-eosin staining) and lowered the levels of CK-MB and cTn-I in the serum of the mouse model of myocardial ischemia(P<0.01). Metabolomics analysis screed out 31 endogenous metabolites in the heart and 35 in the serum as biomarkers of CF in ameliorating the myocardial ischemic injury. These biomarkers were altered by modeling and restored by CF. Six metabolic pathways in the heart and 5 in the serum were enriched based on these metabolic markers. The main integrated pharmacokinetic parameters of CF iridoid glycosides were T_(max)=1 h, t_(1/2)=(1.52±0.05) h in the heart and T_(max)=1 h, t_(1/2)=(1.56±0.50) h in the serum. Both concentration-time curves showed a double-peak phenomenon. In conclusion, CF demonstrated the cardioprotective effect by regulating metabolic pathways such as taurine and hypotaurine metabolism, and pantothenic acid and coenzyme A biosynthesis. The integrated pharmacokinetics reflect the general pharmacokinetic properties of characteristic components in CF.
